Clinical trials located in

Alzira

Alzira city is located in Spain. Currently, 11 clinical trials are being conducted in this city.

Alzira, located in the province of Valencia, Spain, is a city rich in history and culture. Founded by the Arabs, it was a prosperous agricultural center, known for its irrigation systems. Alzira is surrounded by the Parque Natural de la Murta and Casella, offering stunning natural landscapes. The city is famous for its annual Fallas Festival, showcasing elaborate firework displays and intricate sculptures. Alzira also has a significant historical landmark, the Monastery of Santa María de la Murta, a testament to its medieval past.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainSwedenUnited Kingdom
  • Understanding Elinzanetant’s role in Menopause-related Sleep Issues

    The aim of this study is to investigate the use of a new drug called Elinzanetant for menopausal women who struggle with sleep problems. Menopause often causes sleep problems, such as waking up multiple times during the night, which can make life difficult. It may block proteins that cause sleep problems. The study will investigate whether Elinzanetant improves sleep compared with placebo. Researchers will look at how much time women spend awake after falling asleep at night and their total sleep time after 4 and 12 weeks of treatment. Women in the study will receive Elinzanetant or placebo for 12 weeks. The study will last approximately 22 weeks and includes check-ups including blood and urine tests, physical examinations, sleep tests and home recording of sleep quality and hot flashes. Any health problems that arise during the study will be recorded, whether they are related to the study drugs or not.

    AustriaBelgiumCzechiaGermanyNetherlandsPolandSpain
  • Studying retatrutide for treating obesity and heart disease

    This research study is about a medicine called Retatrutide (also known as LY3437943), which will be tested on people who have obesity and heart disease. The way this study will work is that some people will be given Retatrutide once a week, while others will be given a placebo, which doesn’t have any medicine in it. By doing this, the researchers can see if Retatrutide helps to improve health and if it is safe to use. The study will run for just over two years. AUC is a way for the study to measure the effect of Retatrutide on your body.

    HungaryPolandSlovakiaSpain
  • Benralizumab’s impact on severe asthma study

    The study will examine the effects of a drug called benralizumab on people suffering from a severe type of asthma called eosinophilic asthma. Scientists will do this by using special imaging technology called functional airway imaging (FRI) to take pictures of the lungs before and after treatment. It’s an open-label trial, which means everyone knows that the asthma drug under investigation is benralizumab. The study will last from 15 to 23 weeks. Participants in this study must be adults (18 years of age or older), both men and women, who already have severe eosinophilic asthma. Their asthma is not currently well treated with regular inhalers or other asthma medications. One of the goals of the study is to see if benralizumab helps reduce airway resistance and clear mucus in the lungs. Scientists will measure parameters such as lung volume, airway resistance and mucus accumulation.

    BelgiumFrancePortugalSpainUnited Kingdom
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Assessing new drug impact on chronic diabetic peripheral neuropathic pain

    This study focuses on testing a new medicine called GSK3858279 for people living with chronic Diabetic Peripheral Neuropathic Pain that’s not been well-managed. The medicine will be given to some people selected at random, while others will receive a placebo. It’s important that neither the patient nor the doctors will know who received the drug and who got the placebo. The main aim is to check how well GSK3858279 works for nerve pain. Participants will keep track of their pain daily using a simple scale from 0 (no pain) to 10 (worst imaginable pain). These daily scores will then be added up each week. Additionally, any health issues occurring during the study will be closely monitored, regardless of their relation to GSK3858279.

    FranceGermanyPolandSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Long-term effects and safety of the new drug for narcolepsy

    This study focuses on TAK-861, a drug developed to treat narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). The research aims to evaluate TAK-861’s safety using 160 volunteers who participated in previous narcolepsy studies. The volunteers will be divided into groups and given different doses of TAK-861, depending on their original dose in the parent study. The drug’s effectiveness in alleviating Narcolepsy symptoms such as excessive daytime sleepiness (EDS) and cataplexy episodes will also be observed. This study is intended to last up to 108 weeks with regular visits to the clinic for check-ups. At the end of the study, volunteers will receive a follow-up assessment four weeks after their last dose. While this exploration into the medicine’s long-term effects serves as a new step towards making advancements in narcolepsy treatment.

    FinlandFranceGermanyItalyNetherlandsNorwaySpainSweden

See more clinical trials in other cities in Spain:

.